Technical Analysis for TROV - TrovaGene, Inc.

Grade Last Price % Change Price Change
grade F 1.38 -0.72% -0.01
TROV closed down 0.72 percent on Friday, January 17, 2020, on 44 percent of normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Flat Up
Historical TROV trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Calm After Storm Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Fell Below 50 DMA Bearish -0.72%
MACD Bullish Centerline Cross Bullish -0.72%
Spinning Top Other -0.72%
Calm After Storm Range Contraction -0.72%
Upper Bollinger Band Walk Strength -0.72%
Upper Bollinger Band Touch Strength -0.72%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Trovagene Inc., a development stage molecular diagnostic company, focuses on the development and commercialization of proprietary diagnostic technologies for use in patient/disease screening and monitoring in various medical disciplines. The company's urine-based testing platform facilitates to enhance the management of cancer care and women's healthcare. Its proprietary urine-based molecular diagnostic tests are used to detect transrenal DNA and RNA that are cell-free nucleic acids found in urine. The company's technology is applied in various testing, such as tumor detection and monitoring, prenatal genetic testing, infectious diseases, tissue transplantation, and forensic identification, as well as for patient selection in clinical trials. In addition, it owns rights to nucleophosmin-1, an informative biomarker for acute myeloid leukemia and mutations in the SF3B1 gene that are to be associated with chemotherapy response in chronic lymphocytic leukemia patients. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene Inc. in January 2010. Trovagene Inc. was founded in 1999 and is headquartered in San Diego, California.
Medicine Biotechnology Cancer Healthcare Clinical Medicine Infectious Diseases Oncology Chemotherapy Tumor Acute Myeloid Leukemia Diagnostic Tests Leukemia Chronic Lymphocytic Leukemia Transplantation Biomarkers Cancer Care

Is TROV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 9.64
52 Week Low 0.88
Average Volume 281,756
200-Day Moving Average 2.10
50-Day Moving Average 1.38
20-Day Moving Average 1.30
10-Day Moving Average 1.32
Average True Range 0.13
ADX 18.11
+DI 22.80
-DI 12.40
Chandelier Exit (Long, 3 ATRs ) 1.25
Chandelier Exit (Short, 3 ATRs ) 1.50
Upper Bollinger Band 1.45
Lower Bollinger Band 1.14
Percent B (%b) 0.77
BandWidth 23.63
MACD Line 0.01
MACD Signal Line -0.02
MACD Histogram 0.0265
Fundamentals Value
Market Cap 51.43 Million
Num Shares 37.3 Million
EPS -1.25
Price-to-Earnings (P/E) Ratio -1.10
Price-to-Sales 76.85
Price-to-Book 6.46
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.50
Resistance 3 (R3) 1.50 1.45 1.48
Resistance 2 (R2) 1.45 1.42 1.46 1.47
Resistance 1 (R1) 1.42 1.40 1.42 1.42 1.47
Pivot Point 1.37 1.37 1.38 1.38 1.37
Support 1 (S1) 1.34 1.34 1.34 1.34 1.29
Support 2 (S2) 1.29 1.32 1.30 1.29
Support 3 (S3) 1.26 1.29 1.28
Support 4 (S4) 1.26